Public Policy Initiatives
Safe And Adequate Blood Supply

Nearly 70 percent of primary immune deficient patients use immune globulin intravenous (IGIV) to maintain their health. IGIV is a pooled plasma derivative administered intravenously every three or four weeks that replaces antibodies in patients who are unable to adequately produce these protective proteins themselves. IDF works with the US FDA and the IGIV manufacturers to help to ensure a safe and adequate IGIV supply.

Federal Issues on Blood Safety and Availability

FDA Announces Smallpox Vaccine Guidance for Blood Industry - 12/30/2002

Information about West Nile Virus and Blood Safety - Updated 10/3/2002